Retatrutide is an investigational triple receptor agonist targeting GLP-1, GIP, and glucagon receptors, not yet approved by the MHRA or EMA for routine clinical use in the UK
Patients with specific dietary restrictions or religious considerations often inquire about animal products
Overall, GLP-1 users are mostly Gen X, African American, or Hispanic and have lower incomes than non-users
It now includes oral GLP-1 drugs, amylin combinations, dual agonists, triple agonists, long-acting platforms, and differentiated assets designed for durability, tolerability, access, or broader metabolic indications
Imagine feeling full naturally, having lots of energy, and no need to constantly eat because of something in your body called GLP-1 or Glucagon-like peptide-1
The company advises against use for: Individuals under 18 years of age Pregnant or breastfeeding women People with pre-existing medical conditions who have not consulted a healthcare professional Some customer complaints arise from individuals who purchased the supplement without realizing these restrictions, only to find that it was not suitable for their situation
